PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
PRF Technologies’ GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization
PRF Technologies' GridFeed platform is exploring AI and hyperscale data center power optimization as a strategic growth opportunity, positioning its existing 'predict, simulate, optimize and recommend' engine for operators facing grid-capacity bottlenecks.
The company cites IEA projections that global data center electricity consumption will roughly double from 485 TWh in 2025 to 950 TWh by 2030, with AI-focused data center consumption expected to triple over the same period.
Exploration areas include workload shifting, energy cost optimization, battery charge and discharge strategies, demand response and real-time power allocation; no partnerships, pilots or customers are signed, and DCIM, EMS, storage, hyperscale and utility players are listed only as potential partners.
The initiative follows the September 9, 2026 plan to establish GridFeed and DeepSolar as a standalone wholly owned subsidiary; PRF remains a dual pharma and energy-optimization small-cap whose risk factors cite a history of losses, a need for additional capital, and Nasdaq MVPS/MVPS listing-compliance requirements.